An Activity‐Based Probe Targeting Non‐Catalytic, Highly Conserved Amino Acid Residues within Bromodomains

Melissa D’Ascenzio, Kathryn Pugh, Rebecca Konietzny, G. Berridge, C. Tallant, Shaima Hashem, Octovia Monteiro, Jason R. Thomas, Markus Schirle, Stefan Knapp, Brian D. Marsden, Oleg Fedorov, C. Bountra, Benedikt M. Kessler, Paul E. Brennan

TL;DR

Researchers have developed a novel chemical probe, bromotriazine (BTZ), that can covalently label bromodomain-containing proteins (BRDs). This probe targets conserved lysine and tyrosine residues in the BRD binding pocket, enabling a more comprehensive understanding of these epigenetic regulators and paving the way for new therapeutic strategies.

What Problem Does This Paper Address?

Bromodomains (BRDs) are crucial protein readers that recognize acetylated lysine marks on histones, playing a central role in gene regulation and various cellular processes, including cancer development. While their importance is well-established, developing selective inhibitors and tools to study them has been challenging. Unlike many enzymes, BRDs lack catalytic activity and don't possess readily reactive amino acid residues in their active sites, making traditional activity-based protein profiling (ABPP) difficult. Existing ABPP approaches often rely on photo-affinity labeling, which has limitations. This paper addresses the need for a versatile, covalent probe that can broadly target the diverse family of BRDs, including those lacking obvious reactive residues in their immediate binding pockets.

Methods

The core of this work is the design and synthesis of a novel activity-based probe, bromotriazine (BTZ). This probe was inspired by bromosporine (BSP), a known reversible pan-bromodomain inhibitor. The researchers modified BSP by replacing its methyl sulfonamide scaffold with a dichlorotriazine "warhead" – a reactive electrophile known to label lysine residues. Crucially, they also incorporated a clickable alkyne handle onto the molecule. This handle allows for subsequent attachment of reporter tags (like fluorescent dyes or biotin) for visualization and enrichment of labeled proteins.

The researchers employed several techniques to characterize BTZ:

  • Mass Spectrometry (MS): Used to confirm the formation of covalent adducts between BTZ and BRDs, and to map the specific sites of modification.
  • Crystallography: Employed to determine the precise binding mode and covalent modification site of BTZ with a specific BRD (BRD9), revealing an unexpected dimerization mechanism.
  • Kinetic Assays: Used to measure the rate of covalent modification of various BRDs by BTZ, providing insights into its reactivity and selectivity.
  • Pull-down Assays: Combined with MS/MS analysis, these experiments were used to identify and enrich BRDs from cell lysates that were covalently labeled by BTZ.
  • Chemical Synthesis: The development and synthesis of BTZ and its non-clickable control analog.

Datasets

Not discussed in the paper. The study primarily uses recombinant proteins and cell lysates for experimental validation.

Key Insights and Ideas

  • Targeting Non-Catalytic Residues: The paper demonstrates that it's possible to design covalent probes that target conserved, non-catalytic lysine residues on the rim of the BRD binding pocket, overcoming a major hurdle in BRD ABPP.
  • Tyrosine Labeling: Surprisingly, BTZ was found to efficiently label tyrosine residues in addition to lysines, significantly expanding the potential targets within the BRD family. This was a key discovery, as tyrosine is not typically considered a primary target for such probes.
  • Dimerization Mechanism: Crystallographic studies revealed that BTZ can induce an "interlocked dimer" formation with BRD9, where the probe covalently links two separate BRD molecules. This highlights a novel mechanism of action and potential for allosteric modulation.
  • Broad Spectrum Activity: BTZ shows broad reactivity across different BRD subfamilies, making it a valuable tool for profiling the entire BRD landscape.
  • Scaffold-Driven Selectivity: The reactivity of BTZ appears to be influenced by the reversible binding affinity of its parent scaffold (bromosporine), suggesting that reversible binding can guide covalent labeling.

Key Results

  • BTZ was successfully synthesized with a reactive dichlorotriazine warhead and a clickable alkyne handle.
  • MS/MS analysis confirmed covalent modification of specific lysine residues in BRD4(1) and BRD3(2).
  • Crystallography revealed BTZ covalently labeling a tyrosine residue (Tyr106) in BRD9, leading to an interlocked dimer.
  • Kinetic studies showed BTZ has a high reactivity towards CECR2 (kapp = 12.6 × 10⁻⁴ s⁻¹), which possesses two tyrosine residues.
  • Pull-down experiments in K-562 cells identified enrichment of BRD4, BRD8, and BRD-associated proteins (SMARCA4, SUPT16H) upon BTZ treatment.
  • Competition experiments with a non-clickable analog and a known BET inhibitor (JQ1) provided further validation of BTZ's specificity.

Limitations and Future Work

  • Promiscuity: The authors note that initial attempts to visualize covalent BRD-BTZ adducts using fluorescent dyes were challenging, possibly due to the probe's promiscuity.
  • Unidentified Targets: While BTZ showed enrichment of BRD8, which had not been previously produced recombinantly, further validation is needed to confirm its direct interaction.
  • Off-Target Identification: The pull-down experiments identified Thymosin beta-4 (TMSB4X) as a potential off-target, which was selectively competed by the non-clickable analog and JQ1. This suggests further investigation into BTZ's selectivity profile is warranted.
  • Future Directions: The authors suggest that the design principles behind BTZ could be applied to develop covalent probes for other protein families that possess lysine and/or tyrosine residues near their binding sites. The ability to label tyrosine residues opens new avenues for targeting proteins previously considered difficult to probe with ABPP. Further exploration of the dimerization mechanism induced by BTZ could also lead to novel therapeutic strategies.

Summary updated

Abstract

Bromodomain-containing proteins are epigenetic modulators involved in a wide range of cellular processes, from recruitment of transcription factors to pathological disruption of gene regulation and cancer development. Since the druggability of these acetyl-lysine reader domains was established, efforts were made to develop potent and selective inhibitors across the entire family. Here we report the development of a small molecule-based approach to covalently modify recombinant and endogenous bromodomain-containing proteins by targeting a conserved lysine and a tyrosine residue in the variable ZA or BC loops. Moreover, the addition of a reporter tag allowed in-gel visualization and pull-down of the desired bromodomains.
BibTeX
@inproceedings{dascenzio2018activitybased,
  author = {Melissa D’Ascenzio and Kathryn Pugh and Rebecca Konietzny and G. Berridge and C. Tallant and Shaima Hashem and Octovia Monteiro and Jason R. Thomas and Markus Schirle and Stefan Knapp and Brian D. Marsden and Oleg Fedorov and C. Bountra and Benedikt M. Kessler and Paul E. Brennan},
  title = {{An Activity‐Based Probe Targeting Non‐Catalytic, Highly Conserved Amino Acid Residues within Bromodomains}},
  booktitle = {Angewandte},
  year = {2018},
  doi = {10.1002/anie.201807825},
}
Figure